About M Ventures
M Ventures is an early-stage venture firm investing not only capital, but also time, relationships and expertise into technology companies that use software and the internet to create consumer or enterprise products and solutions.In May 2019, M Ventures merged with Cross Culture Ventures to form MaC Venture Capital.
M Ventures Headquarter Location
Los Angeles, California,
Latest M Ventures News
Aug 20, 2021
本文共2650个字，阅读需7分钟 Series B financing led by Agent CapitalFunding to advance novel NK and T cell modulator IMT-009 for the treatment of solid tumor and hematological cancers with an anticipated IND filing in 1H 2022Expands leadership team with appointment of Chief Business Officer Amanda Wagner, appoints Geeta Vemuri, Agent Capital, and Brian Halak, on behalf of MEC, to Immunitas Board of DirectorsWALTHAM, Mass., Aug. 18, 2021 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series B financing led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP). Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round. As part of the financing, Geeta Vemuri, PhD, MBA, Managing Partner and Founder of Agent Capital, and Brian Halak, PhD, on behalf of MEC will join the Immunitas Board of Directors. "Immunitas has made tremendous strides in the past year. This Series B financing is a key inflection point for the company and will enable us to drive IMT-009 rapidly into the clinic, while continuing to build and validate our pipeline of novel oncology programs," said Jeffrey Goldberg, Chief Executive Officer of Immunitas Therapeutics. "Our single cell technology platform allows our team to incorporate insights from human biology throughout the discovery and development process, enabling us to rapidly move towards serving patients in need. "The Series B funding will be used to advance Immunitas' lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies. Both blockade and knockout of CD161 in preclinical systems have shown enhanced tumor-killing, increases in critical cytokines, and increased survival. The company expects to file its first Investigational New Drug application (IND) in 1H 2022 for IMT-009. This financing builds on the $39 million Series A financing secured in 2019. Immunitas Therapeutics was founded by Kai Wucherpfennig, MD, PhD, Dana-Farber Cancer Institute, K. Dane Wittrup, PhD, the Massachusetts Institute of Technology (MIT), Mario Suvà, MD, PhD, Massachusetts General Hospital (MGH), and Aviv Regev, PhD, MIT. "Immunitas is focused on creating impactful therapies that modulate oncology targets, driven by a cross-functional platform that combines single cell analysis computation and molecular and cellular biology to rapidly identify and validate new targets," said Geeta Vemuri of Agent Capital. "This approach is well suited to provide powerful translational insights into biomarker and indication selection with long-term potential beyond IO. "In addition, Amanda Wagner, MBA, has been appointed Chief Business Officer in recognition of her significant contributions to the company's business and corporate development. Ms. Wagner was one of the earliest employees of Immunitas, joining the company in October 2019 as Vice President of Strategy. Ms. Wagner has more than 15 years of experience in drug discovery, drug development, and medical technology, and has led teams to identify, research, and develop novel immune-modulating therapies. At Immunitas, Ms. Wagner has led the structuring and negotiation of multiple strategic collaborations and driven the progression of the lead program and pipeline. Prior to joining Immunitas, she was Vice President of Corporate Development at Q32 Bio, where she contributed to the company's $46 million Series A. Previously, Ms. Wagner was at Concert Pharmaceuticals, where she managed a $250 million asset sale, directly contributed to the Initial Public Offering, and identified and led the development of a preclinical therapeutic for autoimmune disease, now in Phase 3. Prior to Concert, Ms. Wagner was an early member of the team at UpToDate, Inc. Ms. Wagner also sits on the Board of Directors of the National Alopecia Areata Foundation.About Immunitas TherapeuticsImmunitas is a single cell genomics-based therapeutics company focused on immunology that is advancing multiple programs to the clinic. Immunitas' programs are derived from their platform, a cross-functional, highly integrated, single cell genomics approach that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class NK and T cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. Immunitas is also advancing IMT-073, a dual-target NK and T cell modulator. The company was founded by Longwood Fund with leading scientists from Dana-Farber, MGH, the Broad, and MIT. Since being founded in 2019, Immunitas has raised a total of $97 million in venture funding from a strong syndicate of investors including Longwood Fund, Alexandria, Evotec, Leaps by Bayer, M Ventures, and Novartis Venture Fund (NVF). To learn more, visit www.immunitastx.comAbout Agent CapitalAgent Capital is an international life sciences investment firm that supports disruptive healthcare companies focusing on novel, differentiated therapeutics and treatments that address unmet patient needs. Agent Capital aligns with scientists, entrepreneurs, and other investors to develop the next generation of healthcare innovations, leverages their industry expertise and successful track record to source premier deals, accelerate value, and drive successful exits. Their first fund invested in 15 portfolio companies, majority of them have executed collaborations with major pharmaceutical companies and successfully raised additional capital in the private or public markets. Agent Capital has offices in Boston, Massachusetts.multimedia:https://www.prnewswire.com/news-releases/immunitas-therapeutics-completes-58-million-series-b-financing-to-advance-pipeline-into-the-clinic-and-expand-single-cell-analysis-drug-development-platform-for-immuno-oncology-and-other-diseases-301357418.html 代理资本主导的B轮融资资助开发新的NK和T细胞调节剂IMT-009，用于治疗实体瘤和血液系统癌症，预计将于2022年1h提交IND申请扩大领导团队，任命首席商务官阿曼达·瓦格纳，任命代理资本Geeta Vemuri和代表MEC的Brian Halak为免疫公司董事会成员马萨诸塞州沃尔瑟姆。2021年8月18日/PRNewswire/--基于单细胞基因组学的治疗公司Immunitas Therapeutics（“Immunitas”）今天宣布完成了由Agent Capital牵头的5800万美元B系列融资，参与方包括Medical Excellence Capital(MEC)、120 Capital、Solasta Venture、Mirae Asset、Ono Venture Investment、Mark Foundation for Cancer Research、NS Investment、Brightge（美国癌症协会）和®白血病和淋巴瘤协会治疗加速项目（LLS TAP）。现有投资者Alexandria Venture Investments、Evotec、Leaps by Bayer、M Ventures、Novartis Venture Fund(NVF)和创始投资者Longwood Fund也加入了这一轮。作为融资的一部分，Geeta Vemuri博士，MBA，Agent Capital的管理合伙人和创始人，以及Brian Halak博士，代表MEC将加入Immunitas董事会。免疫治疗公司首席执行官杰弗里·戈德堡（Jeffrey Goldberg）表示：“免疫治疗公司在过去的一年里取得了巨大的进步。此次B轮融资是该公司的一个关键转折点，将使我们能够迅速将IMT-009推向临床，同时继续构建和验证我们新的肿瘤学项目管道。”“我们的单细胞技术平台允许我们的团队在整个发现和开发过程中融入人类生物学的见解，使我们能够迅速为有需要的患者服务。”B系列资金将用于推进Immunitas的主导项目，IMT-009，一种CD161抑制剂，进入临床治疗实体瘤和血液系统恶性肿瘤。在临床前系统中阻断和敲除CD161都显示了增强的肿瘤杀伤作用、关键细胞因子的增加和存活率的提高。该公司预计将在2022年1H为IMT-009提交其第一个研究性新药申请(IND)。这笔融资建立在2019年获得的3900万美元A轮融资的基础上。Immunitas Therapeutics由Dana-Farber癌症研究所Kai Wucherpfennig医学博士、K.Dane Wittrup博士、麻省理工学院(MIT)、麻省理工总医院(MGH)医学博士Mario SUVà，以及麻省理工学院Aviv Regev博士创建。Agent Capital的Geeta Vemuri说：“Immunitas专注于创建调节肿瘤学目标的有影响力的疗法，由一个跨功能平台驱动，该平台结合了单细胞分析计算和分子及细胞生物学，以快速识别和验证新的目标。”“这种方法非常适合为生物标志物和适应症选择提供强大的翻译见解，具有超越IO的长期潜力。”此外，MBA阿曼达·瓦格纳被任命为首席商务官，以表彰她对公司业务和企业发展的重大贡献。瓦格纳女士是免疫公司最早的员工之一，于2019年10月加入公司，担任战略副总裁。瓦格纳女士在药物发现、药物开发和医疗技术方面拥有超过15年的经验，并领导团队识别、研究和开发新的免疫调节疗法。在Immunitas，Wagner女士领导了多个战略合作的结构和谈判，并推动了领导项目和管道的进展。在加入Immunitas之前，她是Q32 Bio的企业发展副总裁，在那里她为该公司4600万美元的a系列做出了贡献。此前，瓦格纳在Concert Pharmaceuticals管理了2.5亿美元的资产出售，直接参与了首次公开发行，并确定和领导了一种治疗自身免疫性疾病的临床前疗法的开发，目前处于第三阶段。在音乐会之前，瓦格纳女士是UpToDate,Inc.团队的早期成员。瓦格纳女士也是国家斑秃基金会的董事会成员。免疫治疗学Immunitas是一家以单细胞基因组学为基础的治疗公司，专注于免疫学，正在向临床推进多个项目。Immunitas的项目来源于他们的平台，这是一种跨功能、高度集成的单细胞基因组学方法，能够在抗体发现和工程的同时快速识别和验证靶点。IMT-009是一种针对CD161的NK和T细胞调节剂，目前正在开发用于治疗实体瘤和血液系统恶性肿瘤。Immunitas也在推进IMT-073，一种双靶NK和T细胞调节剂。该公司由朗伍德基金与来自Dana-Farber、MGH、Broad和麻省理工学院的领先科学家一起创建。自2019年成立以来，Immunitas已从一个强大的投资者辛迪加筹集了总计9700万美元的风险资金，包括朗伍德基金、亚历山大、Evotec、拜耳Leaps、M Ventures和诺华风险基金(NVF)。欲了解更多信息，请访问www.Immunitastx.com关于代理资本Agent Capital是一家国际生命科学投资公司，支持颠覆性医疗保健公司，专注于解决未满足的患者需求的新颖、差异化疗法和治疗。Agent Capital与科学家、企业家和其他投资者结盟，开发下一代医疗保健创新，利用他们的行业专业知识和成功的记录来获得卓越的交易，加速价值，并推动成功退出。他们的第一只基金投资了15家投资组合公司，其中大多数公司与大型制药公司进行了合作，并成功地在私人或公共市场筹集了额外的资本。代理资本在马萨诸塞州波士顿设有办事处。多媒体:https://www.prnewswire.com/news-releases/Immunitas-therapeutics-completes-58-million-series-b-financing-to-advance-pipeline-into-clinic-and-expand-single-celly-analys-drug-development-platform-for-for-for-for-for-for-for-for-for-for-for-for-for-for-for-for-for-for-for-for-for-for-for-for-for-for 以上中文文本为机器翻译，存在不同程度偏差和错误；偶尔因源网页结构局限，内容无法一次完整呈现。请理解并参考原站原文阅读。
M Ventures Team
5 Team Members
M Ventures has 5 team members, including current Senior Vice President, Jasper Bos.